NEW YORK--(BUSINESS WIRE)--
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Corbus Pharmaceuticals Holdings, Inc. (CRBP) resulting from allegations that Corbus may have issued materially misleading business information to the investing public.
On February 28, 2019, an article was published on Seeking Alpha entitled, “Corbus Has Ties to Suspect Investors And A History Of Failed Clinical Trials for Lenabasum.†The article alleges that Corbus “has ties to investors convicted of or alleged to have committed securities fraud†and that its drug candidate, lenabasum, is believed to have “failed its major trials in [systemic sclerosis] and [cystic fibrosis].†On this news, shares of Corbus fell $1.32 per share or nearly 16% to close at $6.94 per share on February 28, 2019.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Corbus investors. If you purchased shares of Corbus, please visit the firm’s website at https://www.rosenlegal.com/cases-1523.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190228006035/en/